PD-325901 is an anticancer chemotherapeutic MEK1/2 and Raf inhibitor that is particularly effective against cancers harboring B-Raf or Ras mutations such as V600E. PD-325901 decreases levels of phosphorylated ERK1/2, cyclin D1, and thymidine kinase 1. PD-325901 also induces cell cycle arrest at the G0/G1 phase, inhibiting proliferation in thyroid cancer cell lines. In vivo, this compound decreases tumor growth and size. Additionally, PD-325901 displays antiviral benefit, synergizing with other treatments in cellular models of influenza infection.